VEGF-A and angiopoietin-2 inhibitor bispecific antibody - MedImmune

Drug Profile

VEGF-A and angiopoietin-2 inhibitor bispecific antibody - MedImmune

Alternative Names: Ang-2-VEGF bispecific antibody - MedImmune

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator MedImmune
  • Class Bispecific antibodies
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 29 Nov 2016 VEGF-A and angiopoietin-2 inhibitor bispecific antibody licensed to AbMed
  • 29 Nov 2016 Preclinical trials in Undefined indication in USA before November 2016 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top